AmCham Slovakia

Access to modern treatment in Slovakia depends on how the medicine reimbursement system is designed and implemented. Although the debate often focuses on technical concepts such as reimbursement categorization, cost-effectiveness, and thresholds, their impact is direct: they determine whether patients can access necessary treatment in a timely, predictable, and equitable way through public health insurance.

This document highlights three key areas identified by AmCham Slovakia: the role of reimbursement categorization in ensuring real access to medicines, the need to consider cost-effectiveness alongside broader patient and societal value, and the potential impact of significantly lower thresholds on the availability of innovative treatment.

The paper also emphasizes the essential role of patient organizations in ensuring that reimbursement decisions reflect not only costs, but also clinical benefit, disease severity, unmet medical need, quality of life, and the wider impact on families and society.

Read the full document below.